Clinical Drug Insights
Statin Side Effects: What the Evidence Actually Shows
The real statin side effect profile: muscle symptoms, liver enzyme changes, diabetes risk and rhabdomyolysis, with actual incidence rates and NPPA pricing.
The Medyzen blog
Clinical Drug Insights
The real statin side effect profile: muscle symptoms, liver enzyme changes, diabetes risk and rhabdomyolysis, with actual incidence rates and NPPA pricing.
Clinical Drug Insights
What clinical literature says about statin side effects, NPPA price-control status of atorvastatin, and why statin side effects availability hospital pharmacy planning matters.

Clinical Drug Insights
A clinical reference on statins for Indian prescribers: mechanism, real side-effect profile, interactions, NPPA pricing and in-house pharmacy stocking.
Clinical Drug Insights
Which statins carry the highest interaction risk, what drug classes trigger rhabdomyolysis and myopathy, and what a hospital pharmacy needs to flag.
Clinical Drug Insights
The drug classes and generic names used for sports injury management in India: topical NSAIDs, oral NSAIDs, muscle relaxants, and where each fits.
Clinical Drug Insights
A clinical overview of sports injury india treatment: RICE/POLICE protocols, topical and oral NSAID evidence, PRP's regulatory status, and hospital stocking.
Clinical Drug Insights
Spinal implant systems, pedicle screw and cage brands registered for sale in India, how their pricing is regulated, and what it means for hospital stocking.
Clinical Drug Insights
Spine surgery insurance coverage in India: IRDAI waiting period rules, CGHS package rates for laminectomy and discectomy, and common claim exclusions.
Clinical Drug Insights
What a hospital pharmacy needs to stock around spine surgery, from antibiotic prophylaxis to gabapentinoids, and why availability gaps cost revenue.
Clinical Drug Insights
Spine surgery in India: procedure types, real complication rates, implant classification, and PM-JAY cost data for prescribing doctors and hospital admins.
Clinical Drug Insights
Spine surgery drug interactions clinicians need to manage: perioperative anticoagulant and NSAID bleeding risk, discontinuation timing, and evidence for each.
Clinical Drug Insights
Spine surgery cost in India explained: PMJAY and CGHS package rates, CDSCO implant classification, and why spinal implants aren't NPPA price-capped.
Clinical Drug Insights
The drug classes behind common sleep medicine names prescribed in India, their regulatory status, and the evidence on each class's safety profile.
Clinical Drug Insights
A clinical overview of sleep medicine india: insomnia drug classes, OSA management, CDSCO scheduling of hypnotics, and hospital pharmacy stocking.
Clinical Drug Insights
Real side-effect data on antihistamines and topical corticosteroids used for skin allergy in India, plus the Schedule H rules and interaction risks doctors need.
Clinical Drug Insights
What the evidence actually shows on skin allergy natural remedies versus antihistamines, for clinicians deciding what a hospital formulary should stock.
Clinical Drug Insights
The drug classes behind skin allergy medicine names available in India — oral antihistamines, topical corticosteroids and calcineurin inhibitors — with generic mapping and sourcing.
Clinical Drug Insights
What Indian dermatology guidelines recommend for urticaria and eczema, which molecules are price-controlled, and why skin allergy medicine availability hospital pharmacy stock is inconsistent.
Clinical Drug Insights
Antihistamine classes, topical corticosteroid risk, and NPPA pricing context for skin allergy medicines prescribed in India — a clinical reference, not a dosing guide.
Clinical Drug Insights
Clinically sourced drug interactions for antihistamines used in skin allergy treatment: CYP3A4 inhibitors, MAOIs, CNS depressants, and QT-prolonging drugs.
Clinical Drug Insights
What antihistamines and topical steroids for skin allergy actually cost in India, how NPPA price control works, and what it means for hospital stocking.
Clinical Drug Insights
Semaglutide side effects for weight loss: real trial-level GI rates, pancreatitis and thyroid warnings, and India's regulatory and pricing position.
Clinical Drug Insights
Every DCGI-approved semaglutide brand name in India after the March 2026 patent expiry, dose forms, indication differences, and what changed on pricing.
Clinical Drug Insights
Semaglutide's regulatory status, pricing shifts and supply reality in India, and what reliable hospital pharmacy stocking of GLP-1 therapy actually requires.